Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.1296 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.1296 | 1 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.1296 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1296 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.1296 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.1296 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.1296 | 1 | 0.5 |
Leishmania major | p450 reductase, putative | 0.1296 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.1296 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.1296 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.1296 | 1 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.1296 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0653 | 0.0151 | 0.0151 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.1149 | 0.7743 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0643 | 0 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.1296 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0801 | 0.2407 | 0.2407 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.1296 | 1 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0801 | 0.2407 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.1296 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.1149 | 0.7743 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.1296 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.1296 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0643 | 0 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.1296 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.1296 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.1296 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.1296 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.1296 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 1.5 mg kg-1 | Antiallergic activity was evaluated by inhibition of allergen-induced bronchospasm in male Harlan-Wistar rats when administered intraduodenally 15 min prior to antigen challenge | ChEMBL. | 6161252 |
ED50 (functional) | = 2.1 mg kg-1 | In vivo bronchodilator activity in methacholine (intravenous) induced bronchospasm in male Harlan-Sprague-Dawley rats when administered intraduodenally | ChEMBL. | 6161252 |
ED50 (functional) | = 10.6 mg kg-1 | Antiallergic activity was evaluated by passive cutaneous anaphylaxis test in egg albumin sensitized male Harlan-Sprague-Dawley rats when administered perorally | ChEMBL. | 6161252 |
IC50 (functional) | = 3.7 ug ml-1 | In vitro bronchodilator activity in isolated guinea pig tracheal spiral preparation | ChEMBL. | 6161252 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.